| 189 5.35 (2.91%) | 02-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 229.41 | 1-year : | 241.84 |
| Resists | First : | 196.41 | Second : | 207.05 |
| Pivot price | 188.33  |
|||
| Supports | First : | 179.19 | Second : | 149.09 |
| MAs | MA(5) : | 186.57 |
MA(20) : | 189.8 |
| MA(100) : | 192.58 |
MA(250) : | 152.21 |
|
| MACD | MACD : | -2.7 |
Signal : | -2.5 |
| %K %D | K(14,3) : | 26.8 |
D(3) : | 27.3 |
| RSI | RSI(14): 48.3 |
|||
| 52-week | High : | 212.49 | Low : | 93.58 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LGND ] has closed below upper band by 46.6%. Bollinger Bands are 8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 191.7 - 192.86 | 192.86 - 193.97 |
| Low: | 181.2 - 182.53 | 182.53 - 183.81 |
| Close: | 186.92 - 188.92 | 188.92 - 190.83 |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Tue, 24 Feb 2026
LGND Analyst Rating Update: HC Wainwright & Co. Raises Price Tar - GuruFocus
Tue, 17 Feb 2026
Ligand Pharmaceuticals (LGND) Stock Analysis: A Biotech Powerhouse with 32% Upside Potential - DirectorsTalk Interviews
Sat, 14 Feb 2026
Assessing Ligand Pharmaceuticals (LGND) Valuation After Recent Mixed Share Price Performance - Yahoo Finance
Thu, 12 Feb 2026
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewswire
Thu, 12 Feb 2026
Biopharma company Ligand to reveal 2025 results Feb. 26 - Stock Titan
Thu, 12 Feb 2026
Ligand Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Call Scheduled for February 26, 2026 - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 20 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 106.8 (%) |
| Shares Short | 1,280 (K) |
| Shares Short P.Month | 1,250 (K) |
| EPS | 2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 48.34 |
| Profit Margin | 19.3 % |
| Operating Margin | 46.8 % |
| Return on Assets (ttm) | 1.4 % |
| Return on Equity (ttm) | 5.4 % |
| Qtrly Rev. Growth | 122.8 % |
| Gross Profit (p.s.) | 7.86 |
| Sales Per Share | 12.76 |
| EBITDA (p.s.) | 3.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 32 (M) |
| Levered Free Cash Flow | 98 (M) |
| PE Ratio | 83.62 |
| PEG Ratio | 0 |
| Price to Book value | 3.9 |
| Price to Sales | 14.8 |
| Price to Cash Flow | 116.56 |
| Dividend | 9.35 |
| Forward Dividend | 0 |
| Dividend Yield | 4.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|